Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
1.145
+0.005 (0.44%)
At close: Sep 17, 2026, 4:00 PM EDT
1.140
-0.005 (-0.44%)
After-hours: Sep 17, 2026, 4:10 PM EDT
Cocrystal Pharma Revenue
Cocrystal Pharma had revenue of $105.00K in the quarter ending June 30, 2026.
Revenue (ttm)
$330.00K
Revenue Growth
n/a
P/S Ratio
66.55
Revenue / Employee
$33,000
Employees
10
Market Cap
22.06M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 2.01M | -4.55M | -69.32% |
| Dec 31, 2019 | 6.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 78.00K | 69.00K | 766.67% |
| Dec 31, 2014 | 9.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 12.61M | -2.65M | -17.36% |
| Dec 31, 2010 | 15.25M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
COCP News
- 8 days ago - Cocrystal Pharma doses last subject in norovirus challenge study - TheFly
- 8 days ago - Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment - GlobeNewsWire
- 4 weeks ago - Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors - GlobeNewsWire
- 6 weeks ago - Cocrystal Pharma announces $5M investment from Opko Health - TheFly
- 6 weeks ago - Cocrystal Pharma announces $5M private placement with Opko Health - TheFly
- 6 weeks ago - Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewsWire
- 3 months ago - Cocrystal co-CEOs Sam Lee and Jim Martin step down, James Sapirstein succeeds - TheFly
- 3 months ago - Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer - GlobeNewsWire